CVS jumps as TD Cowen lifts price target to $110, keeps buy
CVS shares rose after a same-day analyst action that lifted the firm’s price target to $110 while reiterating a buy rating. The move followed CVS’s recently reported strong Q1 2026 results and higher full-year 2026 guidance, which remained in focus today.
1) What happened today
On May 12, 2026 (U.S. market time), CVS moved higher after an analyst note cited as a catalyst for the stock’s strength, raising the price target to $110 from $105 while maintaining a buy rating.
2) Why it matters
A same-day target increase can act as a near-term catalyst by pulling forward incremental demand from investors who anchor to revised valuation frameworks, especially when it reinforces an already-improving narrative around earnings durability and guidance.
3) Context investors are using
The analyst action landed shortly after CVS reported strong Q1 2026 results and raised full-year 2026 guidance (released May 6, 2026), keeping the post-earnings reassessment cycle active and supporting positive momentum in the shares.